| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914783 | Molecular Oncology | 2015 | 18 Pages |
Abstract
The integration of chromatin regulators as clinical biomarkers, in particular the histone chaperone HJURP, will help guide patient substratification and treatment options for low-risk luminal A breast carcinoma patients.
Keywords
PARPMCMCENP-AEZH2DMFSRPLP0RPPABCSSDFIASF1TCGAanti-silencing function 1Centromere protein ABLCDFSPGREMACAF-1MKi67MFIHJURPribosomal protein large P0progesterone receptor geneReverse phase protein arraysEsr1enzyme-linked immunosorbent assaysThe cancer genome atlasEpigeneticsImmunohistochemistryIHCdisease-free survivalbreast cancer specific survivalELISAenhancer of zeste homolog 2distant metastasis-free survivalchromatin assembly factor 1Disease-free intervalBiomarkersminichromosome maintenanceAfaPoly(ADP-ribose) polymeraseprognosisEstrogen receptor geneChromatinEstrogen receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
RocÃo Montes de Oca, Zachary A. Gurard-Levin, Frédérique Berger, Haniya Rehman, Elise Martel, Armelle Corpet, Leanne de Koning, Isabelle Vassias, Laurence O.W. Wilson, Didier Meseure, Fabien Reyal, Alexia Savignoni, Bernard Asselain,